New data presented today at the 'Gene to Clinic' meeting taking place at the Royal College of Physicians in London, England, reinforce Enbrel's ability to clear skin in patients with psoriatic arthritis, an inflammatory and progressive disease associated with psoriasis. Results from the pioneering PRESTA (Psoriasis Randomized Etanercept STudy in Subjects with Psoriatic Arthritis) study showed that at 24 weeks, two out of three patients with psoriatic arthritis (70% taking 50mg Enbrel twice-weekly and 62% taking 50mg once-weekly) showed a 75% improvement in the psoriasis area-and-severity index (PASI 75)1. PRESTA is the first and largest study of its kind where both dermatologists and rheumatologists have come together to investigate the positive effects of Enbrel in this specific patient population.
Psoriatic arthritis is an inflammatory disease that affects both the skin and joints, where the skin symptoms usually appear before the joint symptoms. Despite the potentially serious impact of the disease, it is difficult to make an accurate diagnosis.
Prof Wolfram Sterry, PRESTA study investigator and Director of the Clinic for Dermatology, Venereology and Allergology at the Charit?© Berlin, Germany, says: "Up to 40% of psoriasis patients will go on to develop psoriatic arthritis and therefore dermatologists are in an ideal position to screen for psoriatic arthritis and provide early therapeutic intervention or referral in order to prevent disease progression."
The PRESTA study results demonstrated that Enbrel 50mg once-weekly or twice-weekly provides improvement of skin symptoms which continue to improve over time. In particular:
At only 12 weeks, over half (55%) of patients taking Enbrel 50mg twice-weekly and more than one third (36%) of patients taking Enbrel 50mg once-weekly showed a 75% improvement in the psoriasis area-and-severity index (PASI 75)1
After 24 weeks, over two thirds (70%) of patients taking Enbrel (50mg twice-weekly for 12 weeks, followed by 50mg once-weekly for 12 weeks) showed a 75% improvement in the psoriasis area-and-severity index (PASI 75), demonstrating that skin clearance continues to improve with Enbrel, even after Enbrel's dose is reduced1
Almost two thirds (62%) of patients treated throughout with 50mg once-weekly also went on to achieve PASI 75 by week 241
In addition, approximately three out of four patients (72-77%) taking Enbrel showed joint improvement, as measured by the Psoriatic Arthritis Response Criteria (PsARC), at only 12-weeks and maintained this improvement at 24-weeks (shown in both arms of the study)1
Previous research has shown that the skin symptoms in psoriasis patients are associated with a low quality of life comparable to, or even worse than those individuals with other chronic medical disorders, including heart disease2. Further results from the PRESTA study presented today demonstrate that Enbrel not only clears skin, but can also improve patients' quality of life3.
Professor Sterry concluded: "The PRESTA study confirms that treating psoriatic arthritis early and aggressively with Enbrel can effectively clear skin, providing patients with meaningful improvements to their daily lives and offering the hope of preventing irreversible damage to joints."
Both Enbrel dose regimens were well tolerated up to 24 weeks with no new safety signals noted.
Enbrel has a long-established safety profile with over 16 years of proven clinical experience, and is currently the number one prescribed biologic worldwide.
Notes:
PRESTA Study
This randomised, multicentre study enrolled patients with both psoriasis and psoriatic arthritis from 110 global sites. In the double-blind period, patients received either Enbrel 50mg twice weekly (BiW) or 50mg once-weekly (QW) for 12 weeks; in the subsequent open-label period, patients received 50mg once weekly for 12 weeks.
Results showed:
? % Patients ?
ETN 50 mg BiW/QW ETN 50 mg QW P-value
PASI Wk 12 Wk 24 Wk 12 Wk 24 Wk 12 Wk 24
?‰?50% 808674830.0490.185
?‰?75%55703662
Комментариев нет:
Отправить комментарий